Craig Hospital, Englewood, CO, USA.
Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Spinal Cord. 2021 May;59(5):563-570. doi: 10.1038/s41393-020-00606-0. Epub 2021 Jan 25.
Retrospective analysis of treated inpatients compared to expected neurorecovery from a propensity score-matched national database cohort.
Evaluate the effectiveness of buspirone on clinical neurorecovery following traumatic SCI when started during acute inpatient rehabilitation.
University-based hospital in Boston, USA.
Chart review yielded thirty-one individuals with acute, traumatic SCI treated with buspirone during inpatient rehabilitation from 2011-2017. Propensity score matching to a cohort of individuals from the spinal cord injury model systems (SCIMS) national database was completed. Changes in upper extremity motor score (UEMS), lower extremity motor score (LEMS), American Spinal Injury Association Impairment Scale (AIS), neurological level of injury (NLI), and functional impairment measure (FIM) from admission to discharge and discharge to 1 year were computed and compared between matched pairs (buspirone and mean national SCIMs cohort). A local control cohort not treated with buspirone was similarly compared to a matched mean national SCIMs group to identify location-specific effects.
From admission to discharge from inpatient rehabilitation, 95% confidence intervals of changes in UEMS (-2.43 to +2.78), LEMS (-1.02 to +6.02), AIS (-0.04 to +0.35), NLI (-0.42 to +1.08), and FIM (-4.42 to +6.40) were not significantly different between those individuals who received buspirone and their propensity-matched SCIMS cohort. Similarly, changes in these metrics were not significantly different at 1-year follow up. Buspirone group individuals with initial clinically complete SCI demonstrated a higher 1-year conversion rate to incomplete injury (6 out of 14; 42.9%) compared to the matched national SCIMS cohort (14 out of 70; 21.2%, p = 0.047) though this was not significantly different from non-buspirone local controls (p = 0.25).
Retrospective analysis shows no statistically significant difference in gross markers of neurorecovery following acute traumatic SCI when buspirone is initiated indiscriminately during acute inpatient rehabilitation. In individuals with clinically complete SCI, findings suggest possible increased rates of 1-year conversion to incomplete injury.
回顾性分析经倾向性评分匹配全国数据库队列预测神经恢复的住院患者。
评估急性住院康复期间开始使用丁螺环酮对创伤性脊髓损伤后临床神经恢复的有效性。
美国波士顿的一所大学医院。
对 2011 年至 2017 年期间在住院康复期间接受丁螺环酮治疗的 31 名急性创伤性脊髓损伤患者进行病历回顾。完成了与脊髓损伤模型系统(SCIMS)全国数据库中患者队列的倾向评分匹配。从入院到出院以及出院后 1 年,计算并比较了匹配对(丁螺环酮和平均全国 SCIMS 队列)中上肢运动评分(UEMS)、下肢运动评分(LEMS)、美国脊髓损伤协会损伤量表(AIS)、神经损伤水平(NLI)和功能障碍测量(FIM)的变化。同样,将未接受丁螺环酮治疗的局部对照队列与匹配的平均全国 SCIMS 组进行比较,以确定特定部位的影响。
从入院到住院康复出院,接受丁螺环酮治疗的患者与倾向评分匹配的 SCIMS 队列相比,UEMS(-2.43 至 +2.78)、LEMS(-1.02 至 +6.02)、AIS(-0.04 至 +0.35)、NLI(-0.42 至 +1.08)和 FIM(-4.42 至 +6.40)的变化在 95%置信区间内没有显著差异。同样,在 1 年随访时,这些指标的变化也没有显著差异。初始临床完全性脊髓损伤的丁螺环酮组患者在 1 年时转换为不完全性损伤的转化率更高(14 例中有 6 例;42.9%),而匹配的全国 SCIMS 队列(70 例中有 14 例;21.2%,p=0.047),但与非丁螺环酮局部对照相比差异无统计学意义(p=0.25)。
回顾性分析表明,在急性住院康复期间不分青红皂白地开始使用丁螺环酮时,急性创伤性脊髓损伤后神经恢复的总体指标没有统计学上的显著差异。在临床完全性脊髓损伤患者中,结果表明可能会增加 1 年转换为不完全性损伤的发生率。